ArticleCytoJournal2025
Study on the correlation between Interleukin 4 and febrile seizures.
Article in CytoJournal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Febrile seizures (FS) are common in pediatric epilepsy, but their precise etiology remains unclear. Although cytokines such as interleukin (IL)-4, IL-1, and IL-6 are known to influence FS fever responses, their specific role is not fully understood. This study aimed to clarify the correlation between IL-4 levels and febrile convulsions, exploring molecular mechanisms through bioinformatics and animal experiments to enhance the understanding of FS pathogenesis. Material and Methods: With the GSE28674 dataset, the K-means clustering algorithm was used to select key genes that regulate IL-4 during feature selection. An animal model of FS was developed, and Results: In this study, bioinformatics analysis and K-means clustering identified proto-oncogene (Jun), protooncogene (Fos), and Early growth response-1 (Egr1) as upstream regulators of IL-4. Dual-luciferase reporter assays confirmed that these transcription factors could activate the IL-4 promoter. qPCR and Western blot analyses showed that the messenger RNA (mRNA) and protein expression levels of Jun, Fos, Egr1, and IL-4 in the FS group were significantly higher than those in the normal control (NC) group ( Conclusion: IL-4 and its upstream transcription factors Jun, Fos, and Egr1 may be associated with FS occurrence and development. Moreover, dupilumab appeared to mitigate the symptoms of FS and modulate the associated immune response by blocking the IL-4 receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.